NES
REGN icon

New England Securities’s Regeneron Pharmaceuticals REGN Stock Holding History

New England Securities’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$4K Sell
10
-12
-55% -$4.72K ﹤0.01% 1340
2014
Q3 		$8K Buy
+22
New +$7.37K ﹤0.01% 1165
2014
Q1 		– Sell
-3
Closed -$1K – 1799
2013
Q4 		$1K Buy
+3
New +$863 ﹤0.01% 1564

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

New England Securities's REGN Position: Q4 2014 in Review

New England Securities reduced its Regeneron Pharmaceuticals (REGN) stake by 55% in Q4 2014, selling an estimated $4.72K and leaving 10 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1340.

New England Securities first reported a position in REGN in Q4 2013 and has held it in 3 quarters since. The position peaked at $8K in Q3 2014. 511 funds tracked by Wall St. Rank hold REGN as of Q4 2014.

  • New England Securities held 10 shares of Regeneron Pharmaceuticals worth $4K as of Q4 2014.
  • New England Securities sold 12 Regeneron Pharmaceuticals shares in Q4 2014, an estimated $4.72K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of New England Securities's portfolio in Q4 2014, its #1340 holding.
  • New England Securities first reported a position in Regeneron Pharmaceuticals in Q4 2013 and has held it in 3 quarters since.
  • New England Securities's Regeneron Pharmaceuticals position peaked at $8K in Q3 2014.
  • 511 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2014.

Based on New England Securities's 13F filing for Q4 2014, filed 26 Jan 2015.